# Reduced Antithrombotic Strategy for High Bleeding Risk Patients With Myocardial Infarction

Study · id `cardio:ct-nct05262803` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05262803](<https://clinicaltrials.gov/study/NCT05262803>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05262803

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2808 participants.

## Technical summary

Registry record NCT05262803. Randomized; single masking; primary purpose treatment. Start 2022-06-17 (actual); primary completion 2028-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 2808 participants (planned count; ClinicalTrials.gov record NCT05262803, source copy `cardio:ctgov-nct05262803-2024-03-15`, retrieved 2026-10-26)
- Started: 2022-06-17 (actual) (ClinicalTrials.gov record NCT05262803, source copy `cardio:ctgov-nct05262803-2024-03-15`, retrieved 2026-10-26)
- Primary completion: 2028-12 (anticipated) (ClinicalTrials.gov record NCT05262803, source copy `cardio:ctgov-nct05262803-2024-03-15`, retrieved 2026-10-26)
- Completion: 2028-12 (anticipated) (ClinicalTrials.gov record NCT05262803, source copy `cardio:ctgov-nct05262803-2024-03-15`, retrieved 2026-10-26)
- Countries: Denmark (ClinicalTrials.gov record NCT05262803, source copy `cardio:ctgov-nct05262803-2024-03-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05262803-2024-03-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Reduced Antithrombotic Strategy for High Bleeding Risk Patients With Myocardial Infarction
- Acronym: Dan-DAPT
- Condition: Myocardial Infarction
- Intervention (Genetic): CYP2C19\*2/\*3
- Intervention (Other): Shorter DAPT duration
- Lead sponsor: Rikke Sorensen
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)

## Provenance

Content hash: 840537a0ce0335f8a765955ae353f0dd17d573a7d824c237c23462740e6a6234
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
